Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
136.38
-1.36 (-0.99%)
Dec 20, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Analyst Ratings
Total Analysts
13
Consensus Rating
Strong Buy
Price Target
$191.77
Upside
+40.61%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $160 → $153 | Strong Buy | Maintains | $160 → $153 | +12.19% | Nov 15, 2024 |
| Wedbush | Wedbush | Buy Reiterates $181 | Buy | Reiterates | $181 | +32.72% | Nov 15, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $190 → $180 | Buy | Maintains | $190 → $180 | +31.98% | Nov 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +24.65% | Nov 15, 2024 |
| Stifel | Stifel | Strong Buy Maintains $200 → $207 | Strong Buy | Maintains | $200 → $207 | +51.78% | Nov 15, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +24.65% | Nov 4, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $180 → $174 | Buy | Maintains | $180 → $174 | +27.58% | Oct 23, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $157 → $160 | Strong Buy | Maintains | $157 → $160 | +17.32% | Oct 21, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $175 → $191 | Strong Buy | Maintains | $175 → $191 | +40.05% | Sep 23, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $264 → $289 | Buy | Maintains | $264 → $289 | +111.91% | Sep 17, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $178 → $207 | Strong Buy | Maintains | $178 → $207 | +51.78% | Sep 17, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $191 → $205 | Buy | Maintains | $191 → $205 | +50.32% | Sep 17, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $180 → $190 | Buy | Reiterates | $180 → $190 | +39.32% | Sep 17, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $180 → $200 | Strong Buy | Maintains | $180 → $200 | +46.65% | Sep 17, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +24.65% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $170 | Buy | Reiterates | $170 | +24.65% | Sep 9, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.